The milestone marks the completion of the Lerentang Pharmaceutical company’s manufacturing facility relocation from Shijiazhuang to Xinle City and Hebei Province.
Aoxing Pharma has obtained $269,231 in the form of bank loan interest payment subsidies for relocation of the manufacturing facility in Xinle City and Hebei Province.
These facilities are expected to begin commercial production in mid-2011.
The execution of the commercial production will allow Aoxing Pharma, to supply all 11 of its licensed essential drugs to 29 provinces and municipalities in China (including military regions).
Aoxing Pharma chairman and CEO Zhenjiang Yue said the GMP certification allows them to shift more management and financial resources to the development of narcotics pipeline.
"We look forward to restarting the manufacturing and sale of these drugs in the next few months. As always, we are very appreciative of the local government’s continuous support of Aoxing Pharma," Yue said.